European Heart Journal Supplements最新文献

Correction to: Sudden death in ischemic heart disease. Looking for new predictors: polygenic risk. 更正：缺血性心脏病中的猝死。寻找新的预测因素：多基因风险。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2024-08-20 eCollection Date: 2023-04-01 DOI: 10.1093/eurheartjsupp/suae083

引用次数: 0

Screening and detection of atrial fibrillation in primary care: current practice and future perspectives. 初级保健中心房颤动的筛查和检测：当前实践与未来展望。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2024-07-31 eCollection Date: 2024-07-01 DOI: 10.1093/eurheartjsupp/suae074

Tessa Brik, Ralf E Harskamp, Jelle C L Himmelreich

{"title":"Screening and detection of atrial fibrillation in primary care: current practice and future perspectives.","authors":"Tessa Brik, Ralf E Harskamp, Jelle C L Himmelreich","doi":"10.1093/eurheartjsupp/suae074","DOIUrl":"10.1093/eurheartjsupp/suae074","url":null,"abstract":"Atrial fibrillation (AF) is a common arrhythmia associated with an increased risk of stroke, which can be effectively reduced by prophylaxis initiation and integrated care to reduce cardiovascular risk and AF-related complications. Screening for AF has the potential to improve long-term clinical outcomes through timely AF detection in asymptomatic patients. With the central role of primary care in most European healthcare systems in terms of disease detection, treatment, as well as record keeping, primary care is ideally situated as a setting for AF screening efforts. In this review, we provide an overview of evidence relating to AF screening in primary care. We discuss current practices of AF detection and screening, evidence from AF screening trials conducted in primary care settings, stakeholder views on barriers and facilitators for AF screening in primary care, and important aspects that will likely shape routine primary care AF detection as well as AF screening efforts. Finally, we present a potential outline for a primary care-centred AF screening trial coupled to integrated AF care that could further improve the benefit of AF screening.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"26 Suppl 4","pages":"iv12-iv18"},"PeriodicalIF":1.7,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetics, transcriptomics, metagenomics, and metabolomics in the pathogenesis and prediction of atrial fibrillation. 遗传学、转录组学、元基因组学和代谢组学在心房颤动发病机制和预测中的应用。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2024-07-31 eCollection Date: 2024-07-01 DOI: 10.1093/eurheartjsupp/suae072

Suvi Linna-Kuosmanen, Matti Vuori, Tuomas Kiviniemi, Joonatan Palmu, Teemu Niiranen

{"title":"Genetics, transcriptomics, metagenomics, and metabolomics in the pathogenesis and prediction of atrial fibrillation.","authors":"Suvi Linna-Kuosmanen, Matti Vuori, Tuomas Kiviniemi, Joonatan Palmu, Teemu Niiranen","doi":"10.1093/eurheartjsupp/suae072","DOIUrl":"10.1093/eurheartjsupp/suae072","url":null,"abstract":"The primary cellular substrates of atrial fibrillation (AF) and the mechanisms underlying AF onset remain poorly characterized and therefore, its risk assessment lacks precision. While the use of omics may enable discovery of novel AF risk factors and narrow down the cellular pathways involved in AF pathogenesis, the work is far from complete. Large-scale genome-wide association studies and transcriptomic analyses that allow an unbiased, non-candidate-gene-based delineation of molecular changes associated with AF in humans have identified at least 150 genetic loci associated with AF. However, only few of these loci have been thoroughly mechanistically dissected, indicating that much remains to be discovered for targeted diagnostics and therapeutics. Metabolomics and metagenomics, on the other hand, add to the understanding of AF downstream of the primary substrate and integrate the signalling of environmental and host factors, respectively. These two rapidly developing fields have already provided several correlates of prevalent and incident AF that require additional validation in external cohorts and experimental studies. In this review, we take a look at the recent developments in genetics, transcriptomics, metagenomics, and metabolomics and how they may aid in improving the discovery of AF risk factors and shed light into the molecular mechanisms leading to AF onset.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"26 Suppl 4","pages":"iv33-iv40"},"PeriodicalIF":1.7,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early detection of atrial fibrillation in the digital era, risk factors, treatment options, and the need for new definitions. 数字时代心房颤动的早期检测、风险因素、治疗方案以及对新定义的需求。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2024-07-31 eCollection Date: 2024-07-01 DOI: 10.1093/eurheartjsupp/suae081

Renate B Schnabel, Daniel Engler, Ben Freedman

引用次数: 0

Atrial fibrillation rhythm management: a matter of timing. 心房颤动节律管理：时机问题。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2024-07-31 eCollection Date: 2024-07-01 DOI: 10.1093/eurheartjsupp/suae077

Philipp Krisai, Michael Kühne

引用次数: 0

Social drivers in atrial fibrillation occurrence, screening, treatment, and outcomes: systematic-narrative hybrid review. 心房颤动发生、筛查、治疗和结果的社会驱动因素：系统叙事混合综述。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2024-07-31 eCollection Date: 2024-07-01 DOI: 10.1093/eurheartjsupp/suae073

Lars Frost, Søren Paaske Johnsen, Emelia J Benjamin, Ludovic Trinquart, Nicklas Vinter

{"title":"Social drivers in atrial fibrillation occurrence, screening, treatment, and outcomes: systematic-narrative hybrid review.","authors":"Lars Frost, Søren Paaske Johnsen, Emelia J Benjamin, Ludovic Trinquart, Nicklas Vinter","doi":"10.1093/eurheartjsupp/suae073","DOIUrl":"10.1093/eurheartjsupp/suae073","url":null,"abstract":"The importance of social drivers of health (SDOH) in the occurrence, detection, treatment, and outcome of atrial fibrillation (AF) has attracted increasing attention. Addressing SDOH factors may suggest opportunities to prevent AF and its complications. We aimed to conduct a structured narrative review and summarize current knowledge on the association between race and ethnicity, SDOH, including rural vs. urban habitation, education, income, and neighbourhood, and the risk of AF, its management, and complications. We identified 537 references in PubMed and 473 references in Embase. After removal of duplicates, we screened the abstracts of 975 references, resulting in 113 references that were examined for eligibility. Subsequently, 34 references were excluded leaving 79 references for the review. Evidence of a social gradient in AF incidence and prevelance were conflicting. However, we found substantial evidence indicating social inequities in the detection of AF, access to treatment, and outcomes such as healthcare utilization, bleeding, heart failure, stroke, dementia, work disability, and death. Inequities are reported across various health care systems and constitute a global problem affecting several continents, although data from Africa and South America are lacking. Given the documented social inequities in AF detection, management, and outcomes, there is an urgent need for healthcare systems, policymakers, and society to identify and implement effective interventions that can reduce inequities and improve outcomes in individuals with AF.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"26 Suppl 4","pages":"iv50-iv60"},"PeriodicalIF":1.7,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Screening for atrial fibrillation: the role of CHA₂DS₂-VASc and atrial fibrillation burden. 心房颤动筛查：CHA2DS2-VASc 和心房颤动负荷的作用。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2024-07-31 eCollection Date: 2024-07-01 DOI: 10.1093/eurheartjsupp/suae078

Lucas Yixi Xing, Oliver B Vad, Daniel Engler, Jesper H Svendsen, Søren Z Diederichsen

引用次数: 0

The budget impact of implementing atrial fibrillation-screening in European countries. 欧洲国家实施心房颤动筛查对预算的影响。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2024-07-31 eCollection Date: 2024-07-01 DOI: 10.1093/eurheartjsupp/suae076

Michaela Eklund, Lars Bernfort, Kajsa Appelberg, Daniel Engler, Renate B Schnabel, Carlos Martinez, Christopher Wallenhorst, Giuseppe Boriani, Claire M Buckley, Søren Zöga Diederichsen, Jesper Hastrup Svendsen, Joan Montaner, Tatjana Potpara, Lars-Åke Levin, Johan Lyth

{"title":"The budget impact of implementing atrial fibrillation-screening in European countries.","authors":"Michaela Eklund, Lars Bernfort, Kajsa Appelberg, Daniel Engler, Renate B Schnabel, Carlos Martinez, Christopher Wallenhorst, Giuseppe Boriani, Claire M Buckley, Søren Zöga Diederichsen, Jesper Hastrup Svendsen, Joan Montaner, Tatjana Potpara, Lars-Åke Levin, Johan Lyth","doi":"10.1093/eurheartjsupp/suae076","DOIUrl":"10.1093/eurheartjsupp/suae076","url":null,"abstract":"A budget impact analysis estimates the short-term difference between the cost of the current treatment strategy and a new treatment strategy, in this case to implement population screening for atrial fibrillation (AF). The aim of this study is to estimate the financial impact of implementing population-based AF-screening of 75-year-olds compared with the current setting of no screening from a healthcare payer perspective in eight European countries. The net budget impact of AF-screening was estimated in country-specific settings for Denmark, Germany, Ireland, Italy, Netherlands, Serbia, Spain, and Sweden. Country-specific parameters were used to allow for variations in healthcare systems and to reflect the healthcare sector in the country of interest. Similar results can be seen in all countries AF-screening incurs savings of stroke-related costs since AF treatment reduces the number of strokes. However, the increased number of detected AF and higher drug acquisition will increase the drug costs as well as the costs of physician- and control visits. The net budget impact per invited varied from €10 in Ireland to €122 in the Netherlands. The results showed the increased costs of implementing AF-screening were mainly driven by increased drug costs and screening costs. In conclusion, across Europe, though the initial cost of screening and more frequent use of oral anti-coagulants will increase the healthcare payers' costs, introducing population screening for AF will result in savings of stroke-related costs.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"26 Suppl 4","pages":"iv19-iv32"},"PeriodicalIF":1.7,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: assessing net clinical benefit. 直接口服抗凝药预防装置检测到的心房颤动患者中风：评估临床净获益。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2024-07-31 eCollection Date: 2024-07-01 DOI: 10.1093/eurheartjsupp/suae075

William F McIntyre, Alexander P Benz, Nedim Tojaga, Axel Brandes, Renato D Lopes, Jeff S Healey

{"title":"Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: assessing net clinical benefit.","authors":"William F McIntyre, Alexander P Benz, Nedim Tojaga, Axel Brandes, Renato D Lopes, Jeff S Healey","doi":"10.1093/eurheartjsupp/suae075","DOIUrl":"10.1093/eurheartjsupp/suae075","url":null,"abstract":"Subclinical, device-detected atrial fibrillation (AF) is frequently recorded by pacemakers and other implanted cardiac rhythm devices. Patients with device-detected AF have an elevated risk of stroke, but a lower risk of stroke than similar patients with clinical AF captured with surface electrocardiogram. Two randomized clinical trials (NOAH-AFNET 6 and ARTESiA) have tested a direct oral anticoagulant (DOAC) against aspirin or placebo. A study-level meta-analysis of the two trials found that treatment with a DOAC resulted in a 32% reduction in ischaemic stroke and a 62% increase in major bleeding; the results of the two trials were consistent. The annualized rate of stroke in the control arms was ∼1%. Several factors point towards overall net benefit from DOAC treatment for patients with device-detected AF. Strokes in ARTESiA were frequently fatal or disabling and bleeds were rarely lethal. The higher absolute rates of major bleeding compared with ischaemic stroke while on treatment with a DOAC in the two trials are consistent with the ratio of bleeds to strokes seen in the pivotal DOAC vs. warfarin trials in patients with clinical AF. Prior research has concluded that patients place a higher emphasis on stroke prevention than on bleeding. Further research is needed to identify the characteristics that will help identify patients with device-detected AF who will receive the greatest benefit from DOAC treatment.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"26 Suppl 4","pages":"iv4-iv11"},"PeriodicalIF":1.7,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

May Measurement Month 2021: an analysis of blood pressure screening campaign results from India. 2021 年五月测量月：印度血压筛查活动结果分析。

IF 1.7 4区医学

European Heart Journal Supplements Pub Date : 2024-07-24 eCollection Date: 2024-06-01 DOI: 10.1093/eurheartjsupp/suae059

Anuj Maheshwari, Narsingh Verma, Jalees Fatima, Ajoy Tewari, Jothydev Kesavdev, Preeti Singh Dhoat, Amrit Kaur, Amit Gupta, Saurabh Srivastava, Abhinav Verma, Shivangi Maheshwari, Sajid Ansari, Amitesh Aggarwal, Abhishek Srivastava, Vanshika Arora, Thomas Beaney, Jonathan Clarke, Neil R Poulter

{"title":"May Measurement Month 2021: an analysis of blood pressure screening campaign results from India.","authors":"Anuj Maheshwari, Narsingh Verma, Jalees Fatima, Ajoy Tewari, Jothydev Kesavdev, Preeti Singh Dhoat, Amrit Kaur, Amit Gupta, Saurabh Srivastava, Abhinav Verma, Shivangi Maheshwari, Sajid Ansari, Amitesh Aggarwal, Abhishek Srivastava, Vanshika Arora, Thomas Beaney, Jonathan Clarke, Neil R Poulter","doi":"10.1093/eurheartjsupp/suae059","DOIUrl":"10.1093/eurheartjsupp/suae059","url":null,"abstract":"Raised blood pressure (BP) is the leading preventable risk factor for cardiovascular diseases that makes a major impact on early mortality and morbidity. Recognizing hypertension in the community, educating people about routine BP monitoring, and improving medication compliance are all important steps in detecting, controlling, and managing hypertension. During the course of 5 months, members of the Indian Society of Hypertension organized unique medical indoor and outdoor camps at 100 screening locations around India for the May Measurement Month (MMM) 2021 study. At every location, BP was measured three times, and a questionnaire was completed. Participants known to have hypertension before the study whether taking or not taking treatment were not included (not a normal pre-requisite for exclusion in MMM). The analysis included 15 045 participants in total. After calculating the average of the second and third BP measurements, 16.4% of participants were found to have hypertension based on ≥140/90 mmHg thresholds (2461 out of 15 045). 14.0% of females and 16.4% of males had hypertension. 16.4% of participants had undiagnosed hypertension and were not receiving treatment. The MMM screening campaign has the potential for identifying large numbers of people with undiagnosed hypertension and raising awareness of the importance of raised BP among the general public, medical professionals, policymakers, the government, and the media. Future BP screening campaigns should be larger in scope and involve follow-ups with past participants.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"26 Suppl 3","pages":"iii44-iii47"},"PeriodicalIF":1.7,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11267709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0